Our findings demonstrated that TAM-expressed VSIG4 induced histone H3 lactylation and epigenetically activated SPP1 transcription, which facilitates neutrophil infiltration and impairs antigen-specific immunity, shedding light on targeting VSIG4+ TAMs as a promising strategy for aggressive cancer immunotherapy. This evidence concerns the gene VSIG4 and cancer.